Leukocyte-Reactive Antibodies in Female Blood Donors: The Austrian Experience

Introduction: Antibody-mediated transfusion-related acute lung injury (TRALI) is caused by antibodies against human leukocyte antigens (HLAs) or human neutrophil antigens (HNAs), and is one of the most serious complications associated with transfusion medicine Prevention strategies like testing allo-exposed female blood donors have not yet been introduced nationwide in Austria To assess the need and feasibility of routine leukocyte antibody testing, the prevalence of leukocyte-reactive antibodies in an Austrian female donor population was been determined using classical cell-based methods which were compared with a high-throughput bead-based method Methods: Sera from 1,022 female blood donors were screened using a granulocyte aggregation test (GAT) and a white blood cell immunofluorescence test (WIFT) after retesting and specification of positive samples by granulocyte immunofluorescence test (GIFT) and monoclonal antibody-specific immobilization of granulocyte antigens (MAIGA) Potential HLA reactivities were confirmed using the microbeads assay LabScreenTM Mixed The results in 142 donor sera and 38 well-defined reference sera were investigated by the microbeads assay LabScreenTM Multi and compared with classical cell-based methods Results: Reactivity with either granulocytes and/or lymphocytes was detected in 79 sera (7 7%), with the majority being HLA-specific Antibodies against HNA were obtained in 7 samples (0 7%) The aggregating potential of the detected antibodies was observed in 9 cases (0 9%) Most of the leukocyte-reactive antibodies occurred at a donor age of between 35 and 59 years (n = 61) LabScreen Multi showed good agreement (κ = 0 767) for HNA antibody detection by cell-based assays, but double/multiple specificities (100% of 7 anti-HNA-1b sera) as well as false-negative results (40% of 15 HNA-3-specific sera) occurred Discussion: Leukocyte-reactive antibody screening is advised in Austrian female donors for safe blood transfusion, including single-donor convalescent plasma treatment of COVID-19 that may be implemented soon For the introduction of LabScreen Multi, the combination with GAT should be considered to ensure correct anti-HNA-3a detection